在质瘤细胞中,SETD5 赋予了 TRAIL 阻力诱导
Lakshay Taneja1, Sachin Bhardwaj1, Ajay Kumar Yadav2
1Molecular Cancer Genetics and Signal Transduction laboratory, Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, North Campus, Gate No. 1, Vishwavidyalaya Marg, Mall Road, 44, AH2, New Delhi, 110007, India.
Scientific reports
|September 29, 2025
概括
在质母细胞瘤 (GBM) 中,SETD5 升级调节,促进对瘤坏死因子相关的亡诱导性联结体 (TRAIL) 治疗的耐药性. 抑制SETD5使GBM细胞对TRAIL敏感,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤,通常对传统治疗有抗性.
- 瘤坏死因子相关的诱导亡的配体 (TRAIL) 显示选择性癌细胞诱导亡,但耐药性是GBM的一个主要障碍.
- SETD5是一种基因组甲基转移酶,与癌症有关,但在质瘤生物学方面了解甚少.
研究的目的:
- 调查SETD5在GBM中调节 TRAIL电阻中的作用.
- 探索SETD5作为一种潜在的治疗点,以克服GBM中的TRAIL阻力.
主要方法:
- 使用公共数据集 (TCGA,GTEx,GEPIA2,UALCAN,Gliovis,GSCA) 来分析GBM中的SETD5表达,突变和甲基化.
- 在GBM细胞系 (U87,LN229) 中通过siRNA介导的SETD5敲除,然后进行TRAIL处理.
- 评估细胞亡,生存途径 (西式涂抹),细胞迁移 (伤口愈合试验) 和二维基基因酶表达.
主要成果:
- 在GBM中,SETD5显著上调,特别是在介质细胞和古典亚型中,与生存和免疫逃避途径相关.
- 在SETD5中,SETD5 Knockdown增强了TRAIL诱导的亡,降低了生存标志物 (p-AKT,P-ERK,NF-κB),并增加了亲亡蛋白.
- SETD5 枯竭会降低duebiquitinases (USP5,USP8,USP10) 的调节,这表明它在稳定致癌蛋白质和促进 TRAIL 耐药性方面发挥了作用.
结论:
- SETD5通过调节亡,免疫逃避和二维基酶表达,极大地促进了 TRAIL 耐药性和 GBM 存活率.
- 抑制SETD5使质瘤细胞对TRAIL诱导的亡敏感,突出了其作为治疗点的潜力.
- 针对SETD5提供了一种新的策略,以克服TRAIL耐药性并提高GBM治疗疗效.
更多相关视频
相关概念视频
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...


